779 patents
Page 9 of 39
Utility
Enhancement of CD47 Blockade Therapy by Proteasome Inhibitors
23 Mar 23
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor.
Emma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova
Filed: 17 Aug 22
Utility
Purification of Saccharides
16 Mar 23
The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides, comprising: a) acid hydrolysis; b) a first ultrafiltration/diafiltration-(UFDF-1); b) carbon filtration; c) chromatography; and d) a second ultrafiltration/diafiltration-(UFDF-2).
Ling Chu, Wei Chen, Nishith Merchant, Justin Keith Moran
Filed: 17 Feb 21
Utility
Antibody-drug conjugates with high drug loading
14 Mar 23
The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5.
Pavel Strop, Katherine Anne Delaria, Magdalena Dorywalska, Davide Luciano Foletti, Russell George Dushin, David Louis Shelton, Arvind Rajpal
Filed: 21 Apr 15
Utility
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
14 Mar 23
James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren
Filed: 18 Jan 19
Utility
Glycoconjugation process
14 Mar 23
The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
Filed: 12 Aug 21
Utility
Kras G12D Inhibitors
9 Mar 23
The present invention relates to compounds that inhibit KRas G12D.
Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
Filed: 20 Jul 22
Utility
Anti-E-selectin antibodies, compositions and methods of use
7 Mar 23
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin.
James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
Filed: 21 Jan 21
Utility
Sustained Release Pharmaceutical Compositions
2 Mar 23
Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
Filed: 27 May 22
Utility
Treatment with Site Specific HER2 Antibody-drug Conjugates
2 Mar 23
The present disclosure provides for dosing regimens for the treatment of patients with cancer, particularly a HER2-expressing cancer, with an anti-HER2 antibody-drug conjugate (ADC).
Abraham Leung, Matthew Sung
Filed: 17 Dec 20
Utility
Antibodies Specific for FLT3 and Their Uses
23 Feb 23
The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3).
Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
Filed: 24 Jun 22
Utility
CorrectedCombination Therapies Using CDK Inhibitors
16 Feb 23
This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.
Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
Filed: 21 May 20
Utility
Humanized antibodies
14 Feb 23
Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody.
William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
Filed: 1 Apr 20
Utility
HER2 Mutation Inhibitors
9 Feb 23
Bryan Daniel ELLIS, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Rachel Zoe Rosen, Russell Andrew Shelp
Filed: 25 Jun 22
Utility
Chimeric Antigen Receptors Targeting CD70
9 Feb 23
The disclosure provides CARs (CARs) that specifically bind to CD70.
Surabhi SRIVATSA SRINIVASAN, Niranjana NAGARAJAN, Siler PANOWSKI, Yoon PARK, Tao SAI, Barbra SASU, Thomas VAN BLARCOM, Mathilde DUSSEAUX, Roman GALETTO
Filed: 17 Jun 22
Utility
Once Daily Cancer Treatment Regimen with a PRMT5 Inhibitor
9 Feb 23
A method of treating cancers, including pancreatic cancer, endometrial cancer, non-small cell lung cancer (NSCLC), endometrial cancer, cervical cancer, bladder cancer, head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, esophageal cancer, and other cancers, the method comprising once-daily administration, to a patient in need thereof, of a therapeutically effective amount of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroiso quinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclopentane-1,2-diol having the structure: Formula I or a pharmaceutically acceptable salt thereof.
Meng LI, Kai-Hsin LIAO, Shinji YAMAZAKI
Filed: 15 Dec 20
Utility
Combination Therapy
9 Feb 23
This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.
Jacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
Filed: 4 Oct 22
Utility
PYRAZOLO[1,5-A]PYRAZIN-4-YL Derivatives
9 Feb 23
Matthew Frank BROWN, Alpay DERMENCI, Andrew FENSOME, Brian Stephen GERSTENBERGER, Matthew Merrill HAYWARD, Dafydd Rhys OWEN, Stephen Wayne WRIGHT, Li Huang XING, Xiaojing YANG
Filed: 7 Sep 22
Utility
Pharmaceutical Combinations
9 Feb 23
Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.
Giordano Caponigro, Zhu Alexander Cao
Filed: 16 May 22
Utility
Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
9 Feb 23
The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g.
Gary E. Aspnes, Scott W. Bagley, Wesley Dewitt Clark, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David Andrew Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David Walter Piotrowski, Roger B. Ruggeri
Filed: 7 Dec 20
Utility
Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them
7 Feb 23
Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein.
Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
Filed: 29 Jul 20